RE: punt27 May 2019 22:43
Mani
Sorry but you have a very negative tint on this share.
You forget that Clevegen has now been brought into the equation and whilst at an early phase has shown to have had very positive results relating in partner discussions.
Your whole debate is around Traumakine which the board believe they have resolved.
This alone would increase shareholder optimistic.
As I said before this is a potentially huge opportunity on AIM